Order Article Reprints

Suwa M, Morii I, Kino M, Matsui Y, Yoshinaga M, Takahashi H, Takagi M, Yoshida A, Ichikawa M, Nakajima O, et al. Efficacy and Safety of Rivaroxaban, Apixaban, and Edoxaban for Nonvalvular Atrial Fibrillation Based on Blood Coagulation Activity and Drug Plasma Concentration: SETtsu and North Osaka Multicenter Direct Oral AntiCoagulant (SET DOAC) Registry. Pharmaceuticals. 2024; 17(11):1431. https://doi.org/10.3390/ph17111431

Suwa, Michihiro, Isao Morii, Masaya Kino, Yumie Matsui, Masahiro Yoshinaga, Hiroki Takahashi, Masahiko Takagi, Akira Yoshida, Minoru Ichikawa, Osamu Nakajima, and et al. 2024. "Efficacy and Safety of Rivaroxaban, Apixaban, and Edoxaban for Nonvalvular Atrial Fibrillation Based on Blood Coagulation Activity and Drug Plasma Concentration: SETtsu and North Osaka Multicenter Direct Oral AntiCoagulant (SET DOAC) Registry" Pharmaceuticals 17, no. 11: 1431. https://doi.org/10.3390/ph17111431

Suwa, M., Morii, I., Kino, M., Matsui, Y., Yoshinaga, M., Takahashi, H., Takagi, M., Yoshida, A., Ichikawa, M., Nakajima, O., Tanimura, M., Shimoyama, H., Saitoh, H., Sasaki, I., Suzuki, T., & Uemae, S. (2024). Efficacy and Safety of Rivaroxaban, Apixaban, and Edoxaban for Nonvalvular Atrial Fibrillation Based on Blood Coagulation Activity and Drug Plasma Concentration: SETtsu and North Osaka Multicenter Direct Oral AntiCoagulant (SET DOAC) Registry. Pharmaceuticals, 17(11), 1431. https://doi.org/10.3390/ph17111431